| Bioactivity | Memoquin is an anti-amyloid and anti-oxidant multi-target-directed ligand. Memoquin is an orally active inhibitor of BACE-1 and AChE with IC50 values of 108 and 1.55 nM, respectively. Memoquin is a cognitive enhancer that prevents the Aβ-induced neurotoxicity mediated by oxidative stress. Memoquin can be used for the research of Alzheimer’s disease (AD)[1][2]. |
| Invitro | Memoquin 抑制 hAChE，hAChE 诱导的 Aβ(1-40) 聚集，Aβ(1-42) 自聚集和 BACE-1 的 IC50 值分别为 0.00155，28.3，5.93 和 0.108 μM[2]。Memoquin 具有与 hAChE 结合的特性，Ki 值为 2.6 nM[2]。 |
| In Vivo | Memoquin (7-15 mg/kg；口服，一次) 可挽救 scopolamine 诱导的遗忘模型的记忆缺陷[1]。Memoquin (15 mg/kg；口服，每天 1 次，连续 2-6 天) 6 天治疗可完全挽救 Aβ1-42 诱导的遗忘模型的记忆缺陷[1]。 Animal Model: |
| Name | Memoquin |
| CAS | 616885-87-1 |
| Formula | C38H56N4O4 |
| Molar Mass | 632.88 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Capurro V, et al. Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease. PLoS One. 2013;8(2):e56870. [2]. Cavalli A, et al. A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Ed Engl. 2007;46(20):3689-92. |